With $20 million in new series B cash, Dnatrix Inc. is using one of the mildest, albeit annoying, diseases – the common cold – to fight one of the more virulent and deadly illnesses – recurrent glioblastoma – by way of an oncolytic viral approach that just might succeed where a handful of others could not.